Ocrelizumab Co-Formulated With Rhuph20
Relapsing-remitting Multiple Sclerosis
Hoffmann-La RochePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
79 Active assets in the Relapsing-remitting Multiple Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fingolimod TG Therapeutics, Inc. | Phase 4 | A |
Natalizumab Biogen | Phase 4 | BBB |
Glatiramer University Hospital, Montpellier | Phase 4 | BBB |
Interferon ?1 (human fibroblast protein moiety) Biogen | Phase 4 | BBB |
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER University Hospital, Montpellier | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Ocrelizumab Co-Formulated With Rhuph20 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →